View:
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
--------------------
FORM 8-K
--------------------
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
January 16, 2007
Date of Report (Date of earliest event reported)
--------------------
PRO-PHARMACEUTICALS, INC.
(Exact Name of Registrant as Specified in Charter)
--------------------
NEVADA 000-32877 04-3562325
(State or Other Jurisdiction (Commission File Number) (IRS Employer
of Incorporation) Identification No.)
7 WELLS AVENUE
NEWTON, MASSACHUSETTS
02459
(Address of Principal Executive Offices) (Zip Code)
(617) 559-0033
(Registrant's telephone number, including area code)
--------------------
Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions (see General Instruction A.2. below):
|_| Written communications pursuant to Rule 425 under the Securities Act
(17 CFR 230.425)
|_| Soliciting material pursuant to Rule 14a-12 under the Exchange Act
(17 CFR 240.14a-12)
|_| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange
Act (17 CFR 240.14d-2(b))
|_| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange
Act (17 CFR 240.13e-4(c))
================================================================================
Item 5.02. Departure of Directors or Principal Officers; Election of Directors;
Appointment of Principal Officers.
On January 16, 2007, we received a letter from Burton C. Firtel, one of our
directors, notifying us of Mr. Firtel's resignation from the Board of Directors
of Pro-Pharmaceuticals, Inc. effective immediately. A copy of Mr. Firtel's
resignation letter is filed herewith as Exhibit 17.1.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits.
17.1 Letter of Burton C. Firtel to David Platt, Chief Executive
Officer of Pro-Pharmaceuticals, Inc., dated January 11, 2007
- --------------------------------------------------------------------------------
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
PRO-PHARMACEUTICALS, INC.
Date: January 16, 2007 By: /s/ David Platt
------------------------------------
David Platt
Chief Executive Officer
- --------------------------------------------------------------------------------
EXHIBIT INDEX
Exhibit
Number Exhibit
- ------- ----------------------------------------------------------------
17.1 Letter of Burton C. Firtel to David Platt, Chief Executive
Officer of Pro-Pharmaceuticals, Inc., dated January 11, 2007
Exhibit 17.1
Burton C. Firtel
19533 Island Court Drive
Boca Raton, Florida 33434
Dr. David Platt, CEO
Pro-Pharmaceuticals, Inc.
7 Wells Avenue
Newton, MA. 02459
Dear David,
Effective immediately, I am resigning from the Board of Directors of
Pro-Pharmaceuticals.
This past September, it was suggested that I think about resigning from the
board but remain a "friend" of the company. I found that idea to be a
contradiction.
My recent offer to become an employee and organize a marketing department in the
anticipation of an FDA approval for Davanat was denied. That along with
unfulfilled promises made to me, led me to this decision.
It is my sincere hope that Pro succeeds in its' quest for a drug approval.
Sincerely,
/s/ Burt
Burton C. Firtel
1-11-07